

AGO Recommendations for Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer. Update 2011.

Christoph Thomssen^a Anton Scharl^b Nadia Harbeck^c, on behalf of the AGO Breast Committee

^aFrauenklinik, Martin Luther Universität Halle (Saale),

^bFrauenklinik, Klinikum Amberg,

^cBrustzentrum, Unifrauenklinik Köln, Germany

References

- 1 AGO Recommendations for Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer 2011. www.ago-online.de/index.php?lang=en&site=mamma_guide_topical (download August 2011).
- 2 Alkuwari E, Auger M: Accuracy of fine-needle aspiration cytology of axillary lymph nodes in breast cancer patients: a study of 115 cases with cytologic-histologic correlation. *Cancer* 2008;25:89–93.
- 3 Allison KH: Atypical ductal hyperplasia on vacuum-assisted breast biopsy: suspicion for ductal carcinoma in situ can stratify patients at high risk for upgrade. *Hum Pathol* 2011;42:41–50.
- 4 Amato P, Christophe S, Mellon PL: Estrogenic activity of herbs commonly used as remedies for menopausal symptoms. *Menopause* 2002;9:145–50.
- 5 Andersohn F, Willich SN: Interaction of serotonin reuptake inhibitors with tamoxifen. Avoid coprescribing paroxetine and tamoxifen in women with breast cancer. *BMJ* 2010;340:c783.
- 6 Antoniou AC, Wang X, Fredericksen ZS, et al.: A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. *Nat Genet* 2010;42:885–92.
- 7 Archer DF, Dupont CM, Constantine GD, et al.: Desvenlafaxine for the treatment of vasomotor symptoms associated with menopause: a double-blind, randomized, placebo-controlled trial of efficacy and safety. *Am J Obstet Gynecol* 2009;200:238.e1–238.e10.
- 8 Aubert RE, Stanek EJ, Yao J, et al.: Risk of breast cancer recurrence in women initiating tamoxifen with CYP2D6 inhibitors. *J Clin Oncol* 2009;27(suppl):9s(abstr CRA508).
- 9 Audeh MW, Carmicheal J, Penson RT, et al.: Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. *Lancet* 2010;376:245–51.
- 10 Bakken K, Fournier A, Lund E, et al.: Menopausal hormone therapy and breast cancer risk: impact of different treatments. The European Prospective Investigation into Cancer and Nutrition. *Int J Cancer* 2011;128:144–56.
- 11 Barton DL, Soori GS, et al.: Pilot study of Panax quinquefolius (American ginseng) to improve cancer-related fatigue: a randomized, double-blind, dose-finding evaluation: NCCTG trial N03CA. *Support Care Cancer* 2010;18:179–87.
- 12 Baselga J, Bradbury I, Eidtmann H, et al.; on behalf of the NeoALTTO Study Team. First results of the Neo-ALTTO Trial (BIG 01–06 / EGF 106903): a phase III, randomized, open label, neoadjuvant study of lapatinib, trastuzumab, and their combination plus paclitaxel in women with HER2-positive primary breast cancer. *Cancer Res* 2010;70(24 suppl):82s.
- 13 Baselga J, Gelmon KA, Verma S, et al.: Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. *J Clin Oncol* 2010;28:1138–44.
- 14 Bedard PL, Di Leo A, Piccart-Gebhart MJ: Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer. *Nat Rev Clin Oncol* 2010;7:22–36. Review.
- 15 Belkacémi Y, Fourquet A, Cutuli B, et al.: Radiotherapy for invasive breast cancer: guidelines for clinical practice from the French expert review board of Nice/Saint-Paul de Vence. *Crit Rev Oncol Hematol* 2011;79:91–102.
- 16 Beral V, Reeves G, Bull D, et al.; for the Million Women Study Collaborators: Breast cancer risk in relation to the interval between menopause and starting hormone therapy. *J Natl Cancer Inst* 2011;103:296–305.
- 17 Beral V; Million Women Study Collaborators: Breast cancer and hormone-replacement therapy in the Million Women Study. *Lancet* 2003;362:419–27. Erratum in: *Lancet* 2003;362:1160.
- 18 Berger AM, Kuhn BR, Farr LA, et al.: One-year outcomes of a behavioral therapy intervention trial on sleep quality and cancer-related fatigue. *J Clin Oncol* 2009;27:6033–40.

- 19 Bevilacqua JL, Kattan MW, et al.: Doctor, what are my chances of having a positive sentinel node? A validated nomogram for risk estimation. *J Clin Oncol* 2007;25:3670–9.
- 20 Bijl MJ, van Schaik RH, Lammers LA, et al.: The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users. *Breast Cancer Res Treat* 2009;118:125–30.
- 21 Blackwell KL, Burstein HJ, Storniolo AM, et al.: Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. *J Clin Oncol* 2010;28:1124–30.
- 22 Bower JE: Behavioral symptoms in patients with breast cancer and survivors. *J Clin Oncol* 2008;26:768–77.
- 23 Braendle W, Kuhl H, Mueck A, et al.: (Does hormonal contraception increase the risk for tumors?). *Ther Umsch* 2009;66:129–35. Review.
- 24 Brennan SF: Dietary patterns and breast cancer risk: a systematic review and meta-analysis. *Am J Clin Nutr* 2010;91:1294–302.
- 25 Britton P, Moyle P, Benson JR, et al.: Ultrasound of the axilla: where to look for the sentinel lymph node. *Clin Radiol* 2010;65:373–6.
- 26 Bryant HE, Schultz N, Thomas HD, et al.: Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADPribose) polymerase. *Nature* 2005;434:913–7.
- 27 Buijs C, Mom CH, Willemse PH, et al.: Venlafaxine versus clonidine for the treatment of hot flashes in breast cancer patients: a double-blind, randomized cross-over study. *Breast Cancer Res Treat* 2009;115:573–80.
- 28 Burnell M, Levine MN, Chapman JA, et al.: Cyclophosphamide, epirubicin, and fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node-positive or high-risk node-negative breast cancer. *J Clin Oncol* 2009;28:77–82.
- 29 Byrski T, Gronwald J, Huzarski T, et al.: Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. *J Clin Oncol* 2010;28:375–9.
- 30 Byrski T, Huzarski T, Dent R, et al.: Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. *Breast Cancer Res Treat* 2009;115:359–63.
- 31 Cameron D, Casey M, Press M, et al.: A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. *Breast Cancer Res Treat* 2008;112:533–43.
- 32 Cardoso F, Stordeur S, Vlayen J, et al.: Scientific support of the College of Oncology: update of the national guidelines on breast cancer. Good Clinical Practice (GCP). Brussels, Belgian Health Care Knowledge Centre (KCE), 2010. KCE Reports 143C. D/2010/10,273/77.
- 33 Carson JW, Carson KM, Porter LS, et al.: Yoga of Awareness program for menopausal symptoms in breast cancer survivors: results from a randomized trial. *Support Care Cancer* 2009;17:1301–9.
- 34 CEBM Oxford: www.cebm.net/index.aspx?o=1025 (download August 2011).
- 35 CGHFBC: Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. *Lancet* 2001;358:1389–99.
- 36 Chang HR, Glaspy J, Allison MA, et al.: Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment. *Cancer* 2010;116:4227–37.
- 37 Chang MC, Crystal P, Colgan TJ: The evolving role of axillary lymph node fine-needle aspiration in the management of carcinoma of the breast. *Cancer Cytopathol* 2011;Epub ahead of print.
- 38 Chen X, Lu W, Zheng Y, et al.: Exercise, tea consumption, and depression among breast cancer survivors. *J Clin Oncol* 2010;28:991–8.
- 39 Chlebowski RT, Chen Z, Cauley JA, et al.: Oral bisphosphonate use and breast cancer incidence in postmenopausal women. *J Clin Oncol* 2010;28:3582–90.
- 40 Chlebowski RT: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA, USA: Menopausal hormone therapy influence on cancer incidence and related cancer mortality in the women's health initiative randomized trials. *SABCS 2010*;abstr S6–1.
- 41 Chlebowski RT, Anderson GL, Gass M, et al.; on behalf of the WHI Investigators: Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. *JAMA* 2010;304:1684–92.
- 42 Cianfrocca M, Goldstein LJ: Prognostic and predictive factors in early breast cancer. *Oncologist* 2004;9:606–16.
- 43 Cibula D, Gompel A, Mueck AO, La Vecchia C, Hannaford PC, Skouby SO, Zikan M, Dusek L: Hormonal contraception and risk of cancer. *Hum Reprod Update* 2010;16:631–50.
- 44 Citron ML, Berry DA, Cirincione C, et al.: Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. *J Clin Oncol* 2003;21:1431–9.
- 45 ClinicalTrials.gov: An open-label study of trastuzumab-MCC-DM1 (TDM1) vs. capecitabine-lapatinib in patients with HER2-positive locally advanced or metastatic breast cancer (EMILIA). [//clinicaltrials.gov/show/NCT00829166](http://clinicaltrials.gov/show/NCT00829166) (accessed March 24, 2011).

- 46 Coleman RE, Thorpe HC, Cameron D, et al.: Adjuvant treatment with zoledronic acid in stage II/III breast cancer. The AZURE Trial (BIG 01/04). SABCs 2010;S4–5.
- 47 Collaborative Group on Hormonal Factors in Breast Cancer: Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50,302 women with breast cancer and 96,973 women without the disease. *Lancet* 2002;360:187–95.
- 48 Collins K, Thomas D: Acupuncture and acupressure for the management of chemotherapy-induced nausea and vomiting. *J Am Acad Nurse Pract* 2004;16:76–80.
- 49 Cottet V: Postmenopausal breast cancer risk and dietary patterns in the E3N-EPIC prospective cohort study. *Am J Epidemiol* 2009;170:1257–67.
- 50 Cui Y, Shu XO, et al.: Association of ginseng use with survival and quality of life among breast cancer patients. *Am J Epidemiol* 2006;163:645–53.
- 51 Cummings SR: Prevention of breast cancer in postmenopausal women: approaches to estimating and reducing risk. *J Natl Cancer Inst* 2009;101:384–98.
- 52 De Laurentiis M, Cancellato G, D'Agostino D, et al.: Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. *J Clin Oncol* 2008;26:44–53.
- 53 Deecher DC, Alf inito PD, Leventhal L, et al.: Alleviation of thermoregulatory dysfunction with the new serotonin and norepinephrine reuptake inhibitor desvenlafaxine succinate in ovariectomized rodent models. *Endocrinology* 2007;148:1376–83.
- 54 Denkert C, Loibl S, Noske A, et al.: Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. *J Clin Oncol* 2010;28:105–13.
- 55 Dennert G, Horneber M: Selenium for alleviating the side effects of chemotherapy, radiotherapy and surgery in cancer patients. *Cochrane Database Syst Rev* 2006;3:CD005037.
- 56 Derkx F, Maaskant-Braat AJ, van der Sangen MJ, et al.: Staging and management of axillary lymph nodes in patients with local recurrence in the breast or chest wall after a previous negative sentinel node procedure. *Eur J Surg Oncol* 2010;36:646–51.
- 57 Di Leo A, Jerusalem G, Petruzella L, et al.: Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. *J Clin Oncol* 2010;28:4594–600.
- 58 Ditto KE: SSRI discontinuation syndrome. Awareness as an approach to prevention. *Postgrad Med* 2003;114:79–84. Review.
- 59 Domchek SM, Friebel TM, Singer CF, et al.: Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with breast cancer risk and mortality. *JAMA* 2010;304:967–75.
- 60 Dorjgochoo T, Shu XO, Li HL, et al.: Use of oral contraceptives, intrauterine devices and tubal sterilization and cancer risk in a large prospective study, from 1996 to 2006. *Int J Cancer* 2009;124:2442–9.
- 61 Dumeaux V, Alsaker E, Lund E: Breast cancer and specific types of oral contraceptives: a large Norwegian cohort study. *Int J Cancer* 2003;105:844–50.
- 62 DVO-Leitlinie 2009 zur Prophylaxe, Diagnostik und Therapie der Osteoporose bei Erwachsenen. *Osteologie* 4/2009. www.dv-osteologie.org/uploads/leitlinien/DVO-Leitlinie%202009%20Langfassung_Druck.pdf (download August 2011).
- 63 Early Breast Cancer Trialists' Collaborative Group: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of randomised trials. *Lancet* 2005;365:1687–717.
- 64 Easton DF, Pooley KA, Dunning AM, et al.: Genome-wide association study identifies novel breast cancer susceptibility loci. *Nature* 2007;447:1087–93.
- 65 Edvardsen K, Veierød MB, Brustad M, et al.: Vitamin D-effective solar UV radiation, dietary vitamin D and breast cancer risk. *Int J Cancer* 2011;128:1425–33.
- 66 Eidtmann H, de Boer R, Bundred N, et al.: Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. *Ann Oncol* 2010;21:2188–94.
- 67 Elkins G, Marcus J, et al.: Randomized trial of a hypnosis intervention for treatment of hot flashes among breast cancer survivors. *J Clin Oncol* 2008;26:5022–6.
- 68 Ellis GK, Bone HG, Chlebowski RT, et al.: Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 study. *Breast Cancer Res Treat* 2009;118:81–7.
- 69 Ellis P, Barrett-Lee P, Johnson L, et al.: Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial. *Lancet* 2009;373:1681.
- 70 Evans ML, Pritts E, Vittinghoff E, et al.: Management of postmenopausal hot flashes with venlafaxine hydrochloride: a randomized, controlled trial. *Obstet Gynecol* 2005;105:161–6.
- 71 Ewertz M, Jensen MB, Gunnarsdóttir KA, et al.: Effect of obesity on prognosis after early-stage breast cancer. *J Clin Oncol* 2011;29:25–31.
- 72 Ezzo J, Richardson MA, Vickers A et al.: Acupuncture-point stimulation for chemotherapy-induced nausea or vomiting. *Cochrane Database Syst Rev* 2006;(2):CD002285.

- 73 Farmer H, McCabe N, Lord CJ, et al.: Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. *Nature* 2005;434:917–21.
- 74 FDA: [//www.accessdata.fda.gov/drugsatfda_docs/label/2010/103234s5199lbl.pdf](http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/103234s5199lbl.pdf) (download August 2011)
- 75 Fenlon DR, Corner JL, Haviland JS: A randomized controlled trial of relaxation training to reduce hot flashes in women with primary breast cancer. *J Pain Symptom Manage* 2008;35:397–405.
- 76 Ferguson RJ, Ahles TA, Saykin AJ, et al.: Cognitive-behavioral management of chemotherapy-related cognitive change. *Psychooncology* 2007;16:772–7.
- 77 Fonnebo V and the CAM-Cancer Consortium: Acupuncture and acupressure in the treatment of chemotherapy-associated nausea and vomiting. www.cam-cancer.org, updated February 15, 2011.
- 78 Foulkes WD, Smith IE, Reis-Filho JS: Triple-negative breast cancer. *N Engl J Med* 2010;363:1938–48.
- 79 Friedenreich CM: Physical activity and breast cancer risk: impact of timing, type and dose of activity and population subgroup effects. *Br J Sports Med* 2008;42:636–47.
- 80 Gaffield ME, Culwell KR, Ravi A: Oral contraceptives and family history of breast cancer. *Contraception* 2009;80:372–80.
- 81 Gan TJ, Jiao KR, et al.: A randomized controlled comparison of electro-acupoint stimulation or ondansetron versus placebo for the prevention of postoperative nausea and vomiting. *Anesth Analg* 2004;99:1070–5.
- 82 Gelmon KA, Hirte HW, Robidoux A, et al.: Can we define tumors that will respond to PARP inhibitors? A phase II correlative study of olaparib in advanced serous ovarian cancer and triple-negative breast cancer. *J Clin Oncol* 2010;28(15 suppl):233s(abstr 3002).
- 83 Gerber B: Nutrition and lifestyle factors on the risk of developing breast cancer. *Breast Cancer Res Treat* 2003;79:265–76.
- 84 Gianni L, Eiermann W, Semiglazov V, et al.: Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. *Lancet* 2010;375:377–84.
- 85 Gianni L, Pienkowski T, Im YH, et al.: Neoadjuvant pertuzumab (P) and trastuzumab (H): antitumor and safety analysis of a randomized phase II study ('NeoSphere'). *Cancer Res* 2010;70(24 suppl):82s.
- 86 Gianni L, Lladó A, Bianchi G, et al.: Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer. *J Clin Oncol* 2010;28:1131–7.
- 87 Giuliano AE, Hunt KK, Ballman KV, et al.: Axillary dissection vs. no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. *JAMA* 2011;305:569–75.
- 88 Giuliano AE, McCall L, Beitsch P, et al.: Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. *Ann Surg* 2010;252:426–32; discussion 432–3.
- 89 Giuliano M, Giordano A, Handy BC, et al.: Circulating tumor cells as predictor of metastatic disease spread in patients with breast cancer. *SABCS 2010*;abstr PD04–03.
- 90 Gnant M, Mlineritsch B, Schippinger W, et al.: ABCSG-12 Trial Investigators: Endocrine therapy plus zoledronic acid in premenopausal breast cancer. *N Engl J Med* 2009;360:679–91.
- 91 Goldhirsch A, Ingle JN, Gelber RD, et al.; panel members: Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. *Ann Oncol* 2009;20:1319–29.
- 92 Goldhirsch A, Wood WC, Coates AS, et al.; panel members: Strategies for subtypes – dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. *Ann Oncol* 2011;22:1736–47.
- 93 Gonzalez CA: Diet and cancer prevention: contributions from the European Prospective Investigation into Cancer and Nutrition (EPIC) study. *Eur J Cancer* 2010;46:2555–62.
- 94 Gonzalez-Angulo AM, Litton JK, Broglio KR, et al.: High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. *J Clin Oncol* 2009;27:5700–6.
- 95 Goodwin PJ, Pritchard KI: Obesity and hormone therapy in breast cancer: an unfinished puzzle. *J Clin Oncol* 2010;28:3405–7.
- 96 Goss PE, Ingle JN, et al.: Outcomes of women who were premenopausal at diagnosis of early stage breast cancer. *Cancer Res* 2009;69(suppl 1):487s(abstr 13).
- 97 Graeser MK, Engel C, Rhiem K, et al.: Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. Genome-wide association study identifies novel breast cancer susceptibility loci. *J Clin Oncol* 2009;27:5887–92.
- 98 Greenlee H, Hershman DL, Jacobson JS: Use of antioxidant supplements during breast cancer treatment: a comprehensive review. *Breast Cancer Res Treat* 2009;115:437–52.
- 99 Hackshaw A, Baum M, et al.: Long-term effectiveness of adjuvant goserelin in premenopausal women with early breast cancer. *J Natl Cancer Inst* 2009;101:341–9.

- 100 Haddad P: The SSRI discontinuation syndrome. *J Psychopharmacol* 1998;12:305–13. Review.
- 101 Hadji P, Ziller M, Albert US, et al.: Assessment of fracture risk in women with breast cancer using current vs emerging guidelines. *Br J Cancer* 2010;102:645–50.
- 102 Hammond ME, Hayes DF, Dowsett M, et al.: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. *J Clin Oncol* 2010;28:2784–95. Review. Erratum in: *J Clin Oncol* 2010;28:3543.
- 103 Hankinson SE, Colditz GA, Manson JE, et al.: A prospective study of oral contraceptive use and risk of breast cancer (Nurses' Health Study, United States). *Cancer Causes Control* 1997;8:65–72.
- 104 Hannaford PC, Selvaraj S, Elliott AM, et al.: Cancer risk among users of oral contraceptives: cohort data from the Royal College of General Practitioner's oral contraception study. *BMJ* 2007;335:651.
- 105 Harnett A: Fewer fractions of adjuvant external beam radiotherapy for early breast cancer are safe and effective and can now be the standard of care. Why the UK's NICE accepts fewer fractions as the standard of care for adjuvant radiotherapy in early breast cancer. *Breast* 2009;19:159–62.
- 106 Harris L, Fritsche H, Mennel R, et al.: American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. *J Clin Oncol* 2007;25:5287–312.
- 107 Heaney M, Gardner J, Karasavvas N, et al.: Vitamin C antagonizes the cytotoxic effects of antineoplastic drugs. *Cancer Res* 2008;68:8031–8.
- 108 Hershman DL, McMahon DJ, Crew KD, et al.: Prevention of bone loss by zoledronic acid in premenopausal women undergoing adjuvant chemotherapy persist up to one year following discontinuing treatment. *J Clin Endocrinol Metab* 2010;95:559–66.
- 109 Hershman DL, Neugut AI, Subar M, et al.: Association between prescription co-payment amount and compliance with adjuvant aromatase inhibitor therapy in women with early stage breast cancer. *Cancer Res* 2010;70(24 suppl):91s.
- 110 Hershman DL, Shao T, Kushi LH, et al.: Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. *Breast Cancer Res Treat* 2011;126:529–37.
- 111 Hijal T, Fournier-Bidoz N, Castro-Pena P, et al.: Simultaneous integrated boost in breast conserving treatment of breast cancer: a dosimetric comparison of helical tomotherapy and three-dimensional conformal radiotherapy. *Radiother Oncol* 2010;94:300–6.
- 112 Holloway CL, Panet-Raymond V, Olivetto I: Hypofractionation should be the new 'standard' for radiation therapy after breast conserving surgery. *Breast* 2010;19:163–7.
- 113 Hollowell K, Olmsted CL, Richardson AS, et al.: American Society of Clinical Oncology-recommended surveillance and physician specialty among long-term breast cancer survivors. *Cancer* 2010;116:2090–8.
- 114 Houssami N, Ciatto S, Turner RM, et al.: Preoperative ultrasound-guided needle biopsy of axillary nodes in invasive breast cancer: meta-analysis of its accuracy and utility in staging the axilla. *Ann Surg* 2011;254:243–51.
- 115 Hudis C, Citron M, Berry D, et al.: Five year follow-up of INT C9741: dose-dense (DD) chemotherapy (CRx) is safe and effective. *SABCS 2005*;abstr 41.
- 116 Hughes KS, Schnaper LA, Cirrincione C, et al.: Lumpectomy plus tamoxifen with or without irradiation in women age 70 or older with early breast cancer. *J Clin Oncol* 2010;28(suppl):15s(abstr 507).
- 117 James ML, Lehman M, Hider PN, et al.: Fraction size in radiation treatment for breast conservation in early breast cancer. *Cochrane Database Syst Rev* 2010;(11):CD003860.
- 118 Janni WJ, Harbeck N, Sommer H, et al.: Sequential treatment with epirubicin/cyclophosphamide, followed by docetaxel is equieffective, but less toxic than FEC120 in the adjuvant treatment of breast cancer patients with extensive lymph node involvement: The German ADEBAR Phase III Study. *Cancer Res* 2009;69:604.
- 119 Jinno H, Sakata M, Hayashida T, et al.: A phase II trial of capecitabine and docetaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide (FEC) as preoperative treatment in women with stage II/III breast cancer. *Ann Oncol* 2010;21:1262–6.
- 120 Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R, et al.: FinXX Study Investigators. Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial. *Lancet Oncol* 2009;10:1145–51.
- 121 Kahlenborn C, Modugno F, Potter DM, et al.: Oral contraceptive use as a risk factor for premenopausal breast cancer: a meta-analysis. *Mayo Clin Proc* 2006;81:1290–302.
- 122 Kane RC, McGuinn WD Jr, Dagher R, et al.: Dexrazoxane (Totect): FDA review and approval for the treatment of accidental extravasation following intravenous anthracycline chemotherapy. *Oncologist* 2008;13:445–50.
- 123 Kelly CM, Juurlink DN, Gomes T, et al.: Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. *BMJ* 2010;340:c693.
- 124 Key J: Meta-analysis of studies of alcohol and breast cancer with consideration of the methodological issues. *Cancer Causes Control* 2006;17:759–70.

- 125 King TA, Sakr R, Patil S, et al.: Clinical management factors contribute to the decision for contralateral prophylactic mastectomy. *J Clin Oncol* 2011;29:2158–64.
- 126 Konecny GE, Pegram MD, Venkatesan N, et al.: Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. *Cancer Res* 2006;66:1630–9.
- 127 Koukouras D, Spyropoulos C, Siasos N, et al.: Is sentinel node biopsy reliable in large breast tumors? *Eur J Gynaecol Oncol* 2010;31:80–2.
- 128 Krop IE, Beeram M, Modi S, et al.: Phase I study of trastuzumab-DM 1, an Her2 antibody drug conjugate, given every three weeks to patients with Her2-positive metastatic breast cancer. *J Clin Oncol* 2010;28:2698–704.
- 129 Kumle M, Weiderpass E, Braaten T, et al.: Use of oral contraceptives and breast cancer risk: the Norwegian-Swedish Women's Lifestyle and Health Cohort Study. *Cancer Epidemiol Biomarkers Prev* 2002;11:1375–81.
- 130 Lee A, Fan LT: Stimulation of the wrist acupuncture point P6 for preventing postoperative nausea and vomiting. *Cochrane Database Syst Rev* 2009;(2):CD003281.Review.
- 131 Lee SA, Ross RK, Pike MC: An overview of menopausal oestrogen-progestin hormone therapy and breast cancer risk. *Br J Cancer* 2005;92:2049–58.
- 132 Lee Y, Jin Y, Lim W, et al.: A ginsenoside-Rh1, a component of ginseng saponin, activates estrogen receptor in human breast carcinoma MCF-7 cells. *J Steroid Biochem Mol Biol* 2003;84:463–8.
- 133 Lehman M, Hickey B: The less than whole breast radiotherapy approach. *Breast* 2010;19:180–7.
- 134 Li CI: Alcohol consumption and risk of postmenopausal breast cancer by subtype: the Women's Health Initiative Observational Study. *J Natl Cancer Inst* 2010;102:1422–31.
- 135 Lockwood K, Moesgaard S, Folkers K: Partial and complete regression of breast cancer in patients in relation to dosage of coenzyme Q10. *Biochem Biophys Res Comm* 1994;199:1504–8.
- 136 Lockwood K, Moesgaard S, et al.: Progress on therapy of breast cancer with vitamin Q10 and the regression of metastasis. *Biochem Biophys Res Comm* 1995;212:172–7.
- 137 Loibl S, Ring A, et al.: Patients with breast cancer during pregnancy-results from a prospective and retrospective registry (GBG 20/ BIG02–03). *Cancer Res* 2010;70(24suppl):S6–2.
- 138 Loibl S, Schwedler K, von Minckwitz G, et al.: Venlafaxine is superior to clonidine as treatment of hot flashes in breast cancer patients – a double-blind, randomized study. *Ann Oncol* 2007;18:689–93.
- 139 Loprinzi CL, Kugler JW, Sloan JA, et al.: Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. *Lancet* 2000;356:2059–63.
- 140 Loprinzi CL, Levitt R, Barton D, et al.: Phase III comparison of depomedroxyprogesterone acetate to venlafaxine for managing hot flashes: North Central Cancer Treatment Group Trial N99C7. *J Clin Oncol* 2006;24:1409–14.
- 141 Loprinzi CL, Pisansky TM, Fonseca R, et al.: Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivors. *J Clin Oncol* 1998;16:2377–81.
- 142 Lord SJ: Breast cancer risk and hormone receptor status in older women by parity, age of first birth, and breastfeeding: a case-control study. *Cancer Epidemiol Biomarkers Prev* 2008;17:1723–30.
- 143 Lund EL, Quistorff B, Spang-Thomsen M, et al.: Effect of radiation therapy on small-cell lung cancer is reduced by ubiquinone intake. *Folia Microbiol* 1998;4:505–6.
- 144 Ma H: Reproductive factors and breast cancer risk according to joint estrogen and progesterone receptor status: a meta-analysis of epidemiological studies. *Breast Cancer Res* 2006;8:R43.
- 145 Mallmann P: Einfluss einer adjuvanten kombinierten Chemo-/Immuntherapie auf immunologische Parameter und den klinischen Verlauf bei Patientinnen mit Mammakarzinom. *Zent Bl Gynakol* 1991;113:697–706.
- 146 Manga GP, Shahi PK, Ureña MM, et al.: Phase II study of neoadjuvant treatment with doxorubicin, docetaxel, and capecitabine (ATX) in locally advanced or inflammatory breast cancer. *Breast Cancer* 2010;17:205–11.
- 147 Marchbanks PA, McDonald JA, Wilson HG, Folger SG, Mandel MG, Daling JR, Bernstein L, Malone KE, Ursin G, Strom BL, et al.: Oral contraceptives and the risk of breast cancer. *N Engl J Med* 2002;46:2025–32.
- 148 Martín M, Seguí MA, Antón A, et al.: GEICAM 9805 Investigators. Adjuvant docetaxel for high-risk, node-negative breast cancer. *N Engl J Med* 2010;363:2200–10.
- 149 Martin RM: Breast-feeding and cancer: the Boyd Orr cohort and a systematic review with meta-analysis. *J Natl Cancer Inst* 2005;97:1446–57.
- 150 Matousek RH, Dobkin PL: Weathering storms: a cohort study of how participation in a mindfulness based stress reduction program benefits women after breast cancer treatment. *Curr Oncol* 2010;17:62–70.
- 151 McNeely ML, Campbell K, Ospina M, et al.: Exercise interventions for upper-limb dysfunction due to breast cancer treatment. *Cochrane Database Syst Rev* 2010;(6):CD005211.
- 152 McNeely ML, Campbell KL, Rowe BH, et al.: Effects of exercise on breast cancer patients and survivors: a systematic review and meta-analysis. *CMAJ* 2006;175:34–41.

- 153 Meindl A, Hellebrand H, Wiek C, et al.: Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. *Nat Genet* 2010;42:410–4.
- 154 Metcalfe K, Gershman S, Lynch HT, et al.: Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. *Br J Cancer* 2011;104:1384–92.
- 155 Milazzo S, Wolf E, Boehm K, et al.: Thymus extracts for cancer. *Cochrane Database Syst Rev* 2011;(2):CD003993.
- 156 Miles DW, Chan A, Dirix LY, et al.: Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. *J Clin Oncol* 2010;28:3239–47.
- 157 Miller K, Wang M, Gralow J, et al.: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. *N Engl J Med* 2007;357:2666–76.
- 158 Modified from American Cancer Society 2010: www.cancer.org/cancer/breastcancer/detailedguide/breast-cancer-risk-factors (download 13/1, 2011).
- 159 Moebus V, Jackisch C, Lueck HJ, et al.: Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study. *J Clin Oncol* 2010;28:2874–80.
- 160 Monti D, Sufian M, Peterson C: Potential role of mind-body therapies in cancer survivorship. *Cancer* 2008;112(suppl):2607–16.
- 161 Morrow GR, Hickok JT, Roscoe JA, et al.: Differential effects of paroxetine on fatigue and depression: a randomized, double-blind trial from the University of Rochester Cancer Center Community Clinical Oncology Program. *J Clin Oncol* 2003;21:4635–41.
- 162 Myung S-K, Kim Y, Ju W, et al.: Effects of antioxidant supplements on cancer prevention: meta-analysis of randomized controlled trials. *Ann Oncol* 2010;21:166–79.
- 163 Nahta R, Esteva FJ: HER2 therapy: molecular mechanisms of trastuzumab resistance. *Breast Cancer Res* 2006;8:215.
- 164 NCCN (National Comprehensive Cancer Network): Clinical Practice Guidelines in Oncology: Breast Cancer, version V.2, 2011; www.nccn.org.
- 165 Nguyen CV: Atypical ductal hyperplasia in directional vacuum-assisted biopsy of breast microcalcifications: considerations for surgical excision. *Ann Surg Oncol* 2011;18:752–61.
- 166 Nichols HB, Berrington de Gonzales A, Lacey JV, Rosenberg PS: Declining incidence of contralateral breast cancer in the United States from 1975–2006. *J Clin Oncol* 2011;29:1564–9.
- 167 Nitz U, Huober J, Lisboa B, et al.: Superiority of sequential docetaxel over standard FE100C in patients with intermediate risk breast cancer: survival results of the randomized intergroup phase III trial EC-Doc. *SABCS 2008*;abstr 78.
- 168 Njeh CF, Saunders MW, Langton CM: Accelerated partial breast irradiation (APBI): a review of available techniques. *Radiat Oncol* 2010;5:90.
- 169 O’Shaughnessy J, Miles D, Gray RJ, et al.: A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC). *J Clin Oncol* 2010;28(suppl 15):1005.
- 170 O’Shaughnessy J, Osborne C, Pippen JE, et al.: Iniparib plus chemotherapy in metastatic triple-negative breast cancer. *N Engl J Med* 2011;364:205–14.
- 171 O’Shaughnessy J, Schwartzberg LS, Dansoet MA, et al.: A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC). *J Clin Oncol* 2011;29(suppl):abstr 1007.
- 172 Offersen BV, Overgaard M, Kroman N, et al.: Accelerated partial breast irradiation as part of breast conserving therapy of early breast carcinoma: a systematic review. *Radiother Oncol* 2009;90:1–13.
- 173 Ohno S, Ohno Y, Suzuki N, et al.: High-dose vitamin C (ascorbic acid) therapy in the treatment of patients with advanced cancer. *Anticancer Res* 2009;29:809–15. Review.
- 174 Ott MJ, Norris RL, Bauer-Wu SM: Mindfulness meditation for oncology patients: a discussion and critical review. *Integr Cancer Ther* 2006;5:98–108.
- 175 Owen JR, Ashton A, Bliss JM, et al.: Effect of radiotherapy fraction size on local tumour control in patients with early-stage breast cancer after local tumour excision: long-term results of a randomised trial. *Lancet Oncol* 2006;7:467–71.
- 176 Pachman DR, Jason MJ, Loprinzi CL: Management of menopause-associated vasomotor symptoms: current treatment options, challenges and future directions. *Int J Womens Health* 2010;2:123–35.
- 177 Partridge AH, Ruddy KJ, Gelber S, et al.: Ovarian reserve in women who remain premenopausal after chemotherapy for early stage breast cancer. *Fertil Steril* 2010;94:638–44.
- 178 (No authors listed): Pathologists’ Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer. *Breast Care (Basel)* 2010;5:185–7.
- 179 Pavlakis N, Schmidt R, Stockler M: Bisphosphonates for breast cancer. *Cochrane Database Syst Rev* 2005;(3):CD003474. Review.

- 180 Penco S: Stereotactic vacuum-assisted breast biopsy is not a therapeutic procedure even when all mammographically found calcifications are removed: analysis of 4,086 procedures. *AJR Am J Roentgenol* 2010;195:1255–60.
- 181 Perez EA, Suman VJ, Davidson NE, et al.: Results of chemotherapy alone, with sequential or concurrent addition of 52 weeks of trastuzumab in the NCCTG N9831 HER2-Positive Adjuvant Breast Cancer Trial. *SABCS 2009*;abstr 80.
- 182 Petru U, Stranz B, Petru C: Effects of proteolytic enzyme therapy with Wobe Mugos against chemotherapy-induced toxicity in breast cancer patients – results of a pilot study. *Wien Med Wochenschr* 2010;160:513–6.
- 183 Polgár C, Van Limbergen E, Pötter R, et al.; GEC-ESTRO breast cancer working group: Patient selection for accelerated partial-breast irradiation (APBI) after breast-conserving surgery: recommendations of the Groupe Européen de Curiethérapie-European Society for Therapeutic Radiology and Oncology (GEC-ESTRO) breast cancer working group based on clinical evidence (2009). *Radiother Oncol* 2010;94:264–73.
- 184 Prentice RL: Low-fat dietary pattern and risk of invasive breast cancer: the Women’s Health Initiative Randomized Controlled Dietary Modification Trial. *JAMA* 2006;295:629–42.
- 185 Pritchard KI, Rolski J, Papai Z, et al.: Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2). *Breast Cancer Res Treat* 2010;123:453–61.
- 186 Quinn JE, Kennedy RD, Mullan PB, et al.: BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. *Cancer Res* 2003;63:6221–8.
- 187 Rack B, Schindlbeck C, Andergassen U, et al.: Prognostic relevance of circulating tumor cells in the peripheral blood of primary breast cancer patients. *SABCS 2010*;abstr S6–5.
- 188 Reddy JP, Levy L, Oh JL, et al.: Long-term outcomes in patients with isolated supraclavicular nodal recurrence after mastectomy and doxorubicin-based chemotherapy for breast cancer. *Int J Radiat Oncol Biol Phys* 2011;80:1453–7.
- 189 Rhiem K, Wappenschmidt B, Bosse K, et al.: Platinum sensitivity in a BRCA1 mutation carrier with advanced breast cancer. *Clin Oncol (R Coll Radiol)* 2009;21:448–50.
- 190 Robertson JF, Llombart-Cussac A, Rolski J, et al.: Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study. *J Clin Oncol* 2009;27:4530–5.
- 191 Rodger A: Should fewer fractions be the new standard for postoperative radiotherapy in patients with early breast cancer? *Breast* 2010;19:157–8.
- 192 Rodriguez AA, Makris A, Wu MF, et al. DNA repair signature is associated with anthracycline response in triple negative breast cancer patients. *Breast Cancer Res Treat* 2010;123:189–96.
- 193 Rojas MP, Telaro E, Moschetti I, et al.: Follow-up strategies for women treated for early breast cancer (Review). *Cochrane Database Syst Rev* 2005;(1):CD001768.
- 194 Rosenberg L, Zhang Y, Coogan PF, et al.: A case-control study of oral contraceptive use and incident breast cancer. *Am J Epidemiol* 2009;169:473–9.
- 195 Sestak I, Distler W, Forbes JF, et al.: Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial. *J Clin Oncol* 2010;28:3411.
- 196 Seynaeve C, Hille E, Hasenburg A, et al.: The impact of body mass index (BMI) on the efficacy of adjuvant endocrine therapy in postmenopausal hormone sensitive breast cancer (BC) patients; exploratory analysis from the TEAM Study. *SABCS 2010*;abstr S2–3.
- 197 Shapiro S: Re: ‘a case-control study of oral contraceptive use and incident breast cancer’. *Am J Epidemiol* 2009;170:802–3; author reply 803–4.
- 198 Shennan C, Payne S, Fenlon D: What is the evidence for the use of mindfulness-based interventions in cancer care? A review. *Psychooncology* 2011;20:681–97.
- 199 Sideras K, Ingle JN, Ames MM, et al.: Coprescription of tamoxifen and medications that inhibit CYP2D6. *J Clin Oncol* 2010;28:2768–76.
- 200 Singh MS, Francis PA, Michael M: Tamoxifen, cytochrome P450 genes and breast cancer clinical outcomes. *Breast* 2011;20:111–8.
- 201 Slamon DJ, Clark GM, Wong SG, et al.: Human breast cancer: Correlation of relapse and survival with amplification of the HER2/neu oncogene. *Science* 1987;235:177–82.
- 202 Smith JE, Richardson J, Hoffman C, et al.: Mindfulness-based stress reduction as supportive therapy in cancer care: systematic review. *J Adv Nurs* 2005;52:315–27.
- 203 Smith KB, Pukall C: An evidence-based review of yoga as a complementary intervention for patients with cancer. *Psychooncology* 2009;18:465–75.
- 204 Smith MT, Perlis ML, Park A, et al.: Comparative meta-analysis of pharmacotherapy and behavior therapy for persistent insomnia. *Am J Psychiatry* 2002;159:5–11.
- 205 Sparano JA, Wang M, Martino S, et al.: Weekly paclitaxel in the adjuvant treatment of breast cancer. *N Engl J Med* 2008;358:1663–71.
- 206 Sparreboom A, Cox MC, et al.: Herbal remedies in the United States: potential adverse interactions with anticancer agents. *J Clin Oncol* 2004;22:2489–503.

- 207 Speroff L, Gass M, Constantine G, et al.: Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomized controlled trial. *Obstet Gynecol* 2008;111:77–87.
- 208 Stanton AL, Ganz PA, Kwan L, et al: Outcomes from the moving beyond cancer psychoeducational, randomized, controlled trial with breast cancer patients. *J Clin Oncol* 2005;23:6009–18.
- 209 START Trialists' Group, Bentzen SM, Agrawal RK, Aird EG, et al.: The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. *Lancet Oncol* 2008;9:331–41.
- 210 START Trialists' Group, Bentzen SM, Agrawal RK, Aird EG, et al.: The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. *Lancet* 2008;371:1098–107.
- 211 Stopeck AT, Lipton A, Body JJ, et al.: Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. *J Clin Oncol* 2010;28:5132–9.
- 212 Streitberger K, Ezzo J, Schneider A, et al.: Acupuncture for nausea and vomiting: an update of clinical and experimental studies. *Auton Neurosci* 2006;129:107–17.
- 213 Su HI, Sammel MD, Green J, et al.: Antimullerian hormone and inhibin B are hormone measures of ovarian function in late reproductive-aged breast cancer survivors. *Cancer* 2010;116:592–9.
- 214 Suzuki R: Alcohol intake and risk of breast cancer defined by estrogen and progesterone receptor status – a meta-analysis of epidemiological studies. *Int J Cancer* 2008;122:1832–41.
- 215 Tassone P, Di Martino MT, Ventura M, et al.: Loss of BRCA1 function increases the antitumor activity of cisplatin against human breast cancer xenografts in vivo. *Cancer Biol Ther* 2009;8:648–53.
- 216 Tennant S, Evans A, Macmillan D, Lee A, et al.: CT staging of loco-regional breast cancer recurrence. A worthwhile practice? *Clin Radiol* 2009;64:885–90.
- 217 Tremblay A, Sheeran L, Aranda SK: Psychoeducational interventions to alleviate hot flashes: a systematic review. *Menopause* 2008;15:193–202.
- 218 Trichopoulos A: Conformity to traditional Mediterranean diet and breast cancer risk in the Greek EPIC (European Prospective Investigation into Cancer and Nutrition) cohort. *Am J Clin Nutr* 2010;92:620–5.
- 219 Tsou HR, Overbeek-Klumpers EG, Hallett WA, et al.: Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity. *J Med Chem* 2005;48:1107–31.
- 220 Tutt A, Robson M, Garber JE, et al.: Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer. *J Clin Oncol* 2009;27(18 suppl):7s(abstr CRA501).
- 221 Tutt A, Robson M, Garber JE, et al.: Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. *Lancet* 2010;376:235–44.
- 222 Underhill C, Toulmonde M, Bonnefoi H: A review of PARP inhibitors: from bench to bedside. *Ann Oncol* 2011;22:268–79.
- 223 Untch M, Gelber RD, Jackisch C, et al.: Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. *Ann Oncol* 2008;19:1090–6.
- 224 Untch M, Rezai M, Loibl S, et al.: Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. *J Clin Oncol* 2010;28:2024–31.
- 225 Untch M, Loibl S, Bischoff J, et al.: Lapatinib vs trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy: primary efficacy endpoint analysis of the GEPARQUINTO STUDY (GBG 44). *Cancer Res* 2010;70(24 suppl):81s.
- 226 Vadiraja HS, Raghavendra RM, et al.: Effects of a yoga program on cortisol rhythm and mood states in early breast cancer patients undergoing adjuvant radiotherapy: a randomized controlled trial. *Integr Cancer Ther* 2009;8:37–46.
- 227 Vaidya JS, Baum M, Tobias JS, et al.: Targeted intra-operative radiotherapy (Targit): an innovative method of treatment for early breast cancer. *Ann Oncol* 2001;12:1075–80.
- 228 Vaidya JS, Baum M, Tobias JS, et al.: Long-term results of targeted intraoperative radiotherapy (Targit) boost during breast-conserving surgery. *Int J Radiat Oncol Biol Phys* 2010;Epub ahead of print.
- 229 Vaidya JS, Joseph DJ, Tobias JS, et al.: Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. *Lancet* 2010;376:91–102.
- 230 Valachis A, Mauri D, Polyzos NP, et al.: Partial breast irradiation or whole breast radiotherapy for early breast cancer: a meta-analysis of randomized controlled trials. *Breast J* 2010;16:245–51.
- 231 Van Dalen EC, Caron HN, Dickinson HO, et al.: Cardioprotective interventions for cancer patients receiving anthracyclines. *Cochrane Database Syst Rev* 2008;(2):CD003917.
- 232 Van la Parra RF, Peer PG, Ernst MF, et al.: Meta-analysis of predictive factors for non-sentinel lymph node metastases in breast cancer patients with a positive SLN. *Eur J Surg Oncol* 2011;37:290–9.
- 233 Van Zee KJ Donna-Marie MS, Manasseh E, et al.: A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy. *Ann Surg Oncol* 2003;10:1140–51.

- 234 Vernon CC, Hand JW, Field SB, et al.: Radiotherapy with or without hyperthermia in the treatment of superficial localized breast cancer: results from five randomized controlled trials. *Int J Radiat Oncol Biol Phys* 1996;35:731–44.
- 235 Veronesi U, Orecchia R, Luini A, et al.: Intraoperative radiotherapy during breast conserving surgery: a study on 1,822 cases treated with electrons. *Breast Cancer Res Treat* 2010;124:141–51.
- 236 Vessey M, Painter R: Oral contraceptive use and cancer. Findings in a large cohort study, 1968–2004. *Br J Cancer* 2006;95:385–9.
- 237 Viale G, Giobbie-Hurder A, Regan MM, et al.: Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1–98 comparing adjuvant tamoxifen with letrozole. *J Clin Oncol* 2008;26:5569–75.
- 238 Von Minckwitz G, Eidtmann H, Rezai M, et al.: Neoadjuvant chemotherapy with or without bevacizumab: primary efficacy endpoint analysis of the GEPARQUINTO Study (GBG 44). *Cancer Res* 2010;70(suppl):86s–87s.
- 239 Von Minckwitz G, Kümmel S, Vogel P, et al.; German Breast Group: Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early non-responsive breast cancer: phase III randomized GeparTrio trial. *J Natl Cancer Inst* 2008;100:542–51.
- 240 Von Minckwitz G, Schwenkglenks M, Skacel T, et al.: Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropaenia management: results from an integrated analysis. *Eur J Cancer* 2009;45:608–17.
- 241 Von Minckwitz G, Untch M, Nüesch E, et al.: Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. *Breast Cancer Res Treat* 2011;125:145–56.
- 242 Wardley AM, Hiller L, Howard HC, et al.; tAnGo Trial Collaborators: tAnGo: a randomised phase III trial of gemcitabine in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy for early breast cancer: a prospective pulmonary, cardiac and hepatic function evaluation. *Br J Cancer* 2008;99:597–603.
- 243 Whelan TJ, Pignol JP, Levine MN, et al.: Long-term results of hypofractionated radiation therapy for breast cancer. *N Engl J Med* 2010;362:513–20.
- 244 Witek-Janusek L, Albuquerque K, Chroniak KR, et al.: Effect of mindfulness based stress reduction on immune function, quality of life and coping in women newly diagnosed with early stage breast cancer. *Brain Behav Immun* 2008;22:969–81.
- 245 Wolff AC, Hammond ME, Schwartz JN, et al.: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. *J Clin Oncol* 2007;25:118–45.
- 246 World Cancer Research Fund and American Institute for Cancer Research: Food, nutrition, physical activity, and the prevention of cancer: a global perspective. Washington DC, USA, AICR, 2007.
- 247 www.fertiprotekt.de.
- 248 Yarnold J, Bentzen SM, Coles C, et al.: Hypofractionated whole-breast radiotherapy for women with early breast cancer: myths and realities. *Int J Radiat Oncol Biol Phys* 2011;79:1–9.
- 249 Yerushalmi R, Hayes MM, Gelmon KA, et al.: A phase II trial of a neoadjuvant platinum regimen for locally advanced breast cancer: pathologic response, long-term follow-up, and correlation with bio-markers. *Clin Breast Cancer* 2009;9:166–72.